Startups
Elixiron employs advances in reverse translational medicine approaches to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody phage display library and a single human B cell antibody cloning platform to develop innovative therapies for malignant, immunological and degenerative diseases. Our two lead pipeline candidates are currently in first-in-human phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF1R kinase activity, is being explored as a potential therapy for Alzheimer's disease and to improve cancer immunotherapy by reducing immune suppression in tumors, and EI-001 is a monoclonal antibody being investigated for treatment of Vitiligo and other immunological disorders.
Overview
Location
Taiwan, Taipei
Employees
11-50
Total raised
$27M
Founded date
2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 19, 2025 | LOTTE HOLDINGS Japan Invests in Elixiron Immunotherapeutics | Elixiron_Logo TOKYO, JAPAN, June 19, 2025 /EINPresswire.com/ -- LOTTE HOLDINGS CO., LTD. (Headquarter: Tokyo, Japan, President and CEO: Genichi Tamatsuka, hereinafter “LOTTE HOLDINGS”) is pleased to announce a strategic investment in the Se... |
| Aug 27, 2021 | Elixiron Immunotherapeutics secures $27M | Elixiron Immunotherapeutics has raised $27 million in a Series A1 round co-led by Pangu Capital and Taiwania Capital. The Taipei, Taiwan-based company is the developer of immunotherapies intended to help patients suffering from cancer, neur... |
| Aug 24, 2021 | Elixiron Immunotherapeutics Inks $27M Series A-1 | SAN FRANCISCO, CA, Elixiron Immunotherapeutics announced the closing of a Series A-1 extension financing round. >> Click here for more funding data on Elixiron Immunotherapeutics >> To export Elixiron Immunotherapeutics fund... |
| Aug 23, 2021 | Fanatics kills a Topps SPAC deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content The Fortune 500—visualized From Qlik If nothing else, it’s proof why startups find v... |
| Aug 23, 2021 | Elixiron Immunotherapeutics Closes $27M Series A-1 Financing Round | Elixiron Immunotherapeutics, Inc., a company developing therapeutics for cancer, neurological diseases and inflammatory disorders, closed a $27m Series A-1 extension financing round, bringing the total Series A-1 raise to $27m. The round wa... |
| Aug 23, 2021 | Fanatics kills a Topps SPAC deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Change your marketer experience and unleash growth for your business From Optimizely... |
| Aug 23, 2021 | Elixiron closes $27M series A for Alzheimer's and vitiligo clinical trials | Elixiron Immunotherapeutics has closed a $27 million series A to test its lead asset in Alzheimer's disease patients and advance a pipeline of immuno-oncology assets. RELATED: Biogen's Aduhelm win opened up market frenzy for Alzheimer's-foc... |
| Aug 23, 2021 | Elixiron closes $27M series A for Alzheimer's and vitiligo clinical trials | Elixiron Immunotherapeutics has closed a $27 million series A to test its lead asset in Alzheimer's disease patients and advance a pipeline of immuno-oncology assets. The biotech has been testing its lead asset, EI-1071, in a phase 1 trial ... |
| Elixiron Immunotherapeutics | “Elixiron Immunotherapeutics” |
Reviews 0
FAQ about Elixiron Immunotherapeutics
When was Elixiron Immunotherapeutics founded?
Elixiron Immunotherapeutics was founded in 2017.
How much funding has Elixiron Immunotherapeutics raised?
Elixiron Immunotherapeutics has raised $27M in total across 1 funding round.
What has the press written about Elixiron Immunotherapeutics?
Parsers VC has collected 10 articles mentioning Elixiron Immunotherapeutics, among them “LOTTE HOLDINGS Japan Invests in Elixiron Immunotherapeutics” (Jun 19, 2025) and “Elixiron Immunotherapeutics secures $27M” (Aug 27, 2021).
Is Elixiron Immunotherapeutics still active?
Yes, Elixiron Immunotherapeutics is active; its latest activity on Parsers VC dates from Jun 11, 2026.